Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
90 hedge funds and large institutions have $265M invested in Concert Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 35 increasing their positions, 12 reducing their positions, and 8 closing their positions.
288% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 8
192% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 12
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
49% more capital invested
Capital invested by funds: $178M → $265M (+$86.8M)
34% more funds holding
Funds holding: 67 → 90 (+23)
9.34% more ownership
Funds ownership: 54.62% → 63.96% (+9.3%)
69% less call options, than puts
Call options by funds: $447K | Put options by funds: $1.46M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.9M |
| 2 |
Morgan Stanley
New York
|
+$6.14M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$5.62M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$4.02M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$3.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.95M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.26M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$4.53M |
| 4 |
WSA
Wall Street Associates
Lajolla,
California
|
-$4.29M |
| 5 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$2.09M |
CNCE Hedge Fund Activity: Q3 2015 in Review
90 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q3 2015, worth a combined $265M — up 49% from $178M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CNCE positions and 8 closed out — a net gain of 23 holders — while 35 added to existing stakes and 12 trimmed.
The largest buyer was Millennium Management, adding an estimated $6.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $9.95M sold.
- 90 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q3 2015, up from 67 in Q2 2015.
- Funds reported $265M of Concert Pharmaceuticals, Inc. stock for Q3 2015, up 49% quarter-over-quarter.
- 31 funds opened new Concert Pharmaceuticals, Inc. positions in Q3 2015 and 8 closed out, a net change of +23 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q3 2015 was Millennium Management, an estimated $6.9M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q3 2015 was RA Capital Management, an estimated $9.95M sold.
Based on aggregated 13F filings for Q3 2015.